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Abstract: Antidepressant use during the gestational period remains a controversial issue. The objective of this study was 
to appraise the quality of the available clinical practice guidelines (CPGs) that includes recommendations for 
antidepressant use during pregnancy. We systematically searched for documents published between January 2000 and 
September 2010 in MEDLINE / TRIP database and on clearinghouses and main scientific societies’ websites. Four 
appraisers evaluated each guideline using the Appraisal of Guidelines for Research and Evaluation tool (AGREE II). 
Intra-class correlation coefficients (ICC) with 95% confidence intervals (CI) were calculated as an overall indicator of 
agreement. Twelve CPGs were included from a total of 539 references. Only two guidelines were specifically addressed 
to pregnant women. The overall agreement among reviewers was high (ICC: 0.94, 95% CI: 0.86-0.98). The mean scores 
and standard deviation (SD) for each of the AGREE II domains were: scope and purpose: 84.4% (12); stakeholder 
involvement: 67.4% (29.8); rigor of development: 68.6% (19.8); clarity and presentation: 83.4% (17.4); applicability: 
44% (37.3); and editorial independence: 62.1% (30.4). After standardizing the scores of the 12 guidelines, 5 were 
considered as being “recommended”, 5 as “recommended with modifications, and 2 as “not recommended”. Among  
the five recommended guidelines, two were specifically conceived to the gestational period. CPGs containing 
recommendations for antidepressant use during pregnancy were of moderate to high quality. Future guidelines should take 
into account the observed drawbacks in some domains, and specifically focus a more in depth approach of depression 
during pregnancy. 
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INTRODUCTION 
 Antidepressant use during the gestational period remains 
a controversial issue [1]. The safety of these drugs during the 
first trimester of pregnancy, a critical period for foetal 
development, has become a major public health concern. 
Some studies suggest that physicians may often under-
prescribe or discontinue antidepressants at the time of 
conception and during pregnancy [2]. On the other hand, 
discontinuation of antidepressant use during pregnancy is 
also associated with maternal relapse of depression and 
withdrawal symptoms, which is not optimal for the mother 
and her child [3]. Consequently, women who wish to 
become pregnant and who suffer from psychiatric disorders 
are faced with the difficult task of deciding whether to 
continue or discontinue their antidepressant treatment during 
pregnancy.  
 Evidence-based clinical practice guidelines (CPGs) for 
antidepressant use during pregnancy can optimize practice,  
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facilitate the implementation of effective interventions 
during gestation and improve pregnancy outcomes [4, 5]. 
These guidelines are made of recommendations systematically 
developed to assist practitioners and patients in making 
optimal health care decisions for specific clinical conditions 
[6]. The aims are to formulate explicit and specific 
recommendations that would be adopted in clinical practice, 
producing better results for the patient, decreasing risks and 
promoting cost-effective practices [7].  
 Considering the prevalence of antidepressant use during 
pregnancy (14-20%) [8, 9], the maternal and neonatal  
risks and benefits associated with their use, and because  
of the lack of consensus among the health care community / 
health policy makers [10], the quality of CPGs addressing 
recommendations for antidepressant use during the antenatal 
period needs to be evaluated. Therefore, the objective of this 
study was to appraise the quality of the available CPGs that 
disclose recommendations on this subject. 
METHODS 
Identification of Guidelines 
 We performed an exhaustive search in databases and 
main electronic resources for CPGs with recommendations 
